Tesamorelin Peptide: Status, Evidence and Sellers

Tesamorelin, sold as Egrifta, is a synthetic version of growth hormone-releasing hormone, approved by the FDA to shrink the excess deep abdominal fat that comes with HIV-associated lipodystrophy in adults. No other GHRH analog holds a full approval backed by phase 3 evidence, which alone separates it from most of what gets sold in this category. Structurally it is the complete 44-amino-acid human GHRH sequence with a trans-2-hexenoic acid group attached at one end, which resists enzymatic breakdown and stretches its plasma half-life to roughly 26 to 38 minutes, considerably longer than the natural hormone's.

The condition it treats involves visceral fat accumulating abnormally, frequently alongside fat disappearing from the limbs, driven partly by antiretroviral therapy and partly by a relative growth hormone deficiency that comes with HIV. Tesamorelin restores the body's own pulsatile GH release and the IGF-1 rise that follows, and that combination breaks down fat preferentially where it has collected around the organs. The phase 3 trials showed significant, durable reductions on CT against placebo, and the approval followed in 2010.

Off-label, it is used to chase visceral fat in people without HIV, to address growth hormone deficiency, to improve liver fat, and for metabolic or cognitive benefits attributed to normalizing the GH and IGF-1 axis. Compounded versions circulate through telehealth providers in the US, but they have no lawful route to exist: tesamorelin's application was deemed a biologics license on March 23, 2020, and the compounding pathways written into the Food, Drug, and Cosmetic Act cover drugs rather than licensed biologics. Whatever is being sold as compounded tesamorelin is not coming from that pathway, and carries none of the standardization the branded product does. Grade A for the approved indication, on multiple phase 3 randomized trials; grade B for the off-label metabolic uses, where the mechanism is sound but the data are smaller or come from secondary endpoints.

It binds GHRH receptors on the somatotroph cells of the anterior pituitary, switching on adenylyl cyclase and cAMP signaling, which drives GH out in pulses. Unlike injected growth hormone, it does not bypass the hypothalamic-pituitary axis. It amplifies pulses the body is already generating, so feedback through somatostatin and circulating IGF-1 stays intact. GH therefore rises within physiological range rather than well above it, which is the most likely explanation for how favorably it behaved in the trials [1].

Higher GH prompts the liver to make more IGF-1. Both hormones switch on hormone-sensitive lipase and suppress lipoprotein lipase inside fat cells, which tips the balance toward breaking fat down. Visceral fat responds to that more readily than fat under the skin, which is why the reduction shows up where it does. There is also an effect on liver fat that runs independently of any change in visceral volume, possibly through GH receptors in the liver itself [6], and evidence that the quality of fat tissue improves (lipid content within muscle and liver) beyond what a volume measurement would capture [4].

Two independent phase 3 randomized trials and a pooled analysis carry the weight here. The first enrolled 412 patients with HIV and abdominal fat accumulation into a 26-week double-blind placebo-controlled trial [1]. Daily 2 mg subcutaneous dosing cut visceral fat on CT by a mean of 15.2%, while it rose 5.0% on placebo. IGF-1 rose about 81%. Both patients and their physicians rated abdominal appearance as meaningfully improved. HbA1c did not differ significantly between the arms at 26 weeks.

A follow-up trial with a blinded, rerandomized extension to 52 weeks [2] found visceral fat down about 11% at 26 weeks and about 18% at 52 weeks in patients who stayed on the drug, and returning in patients moved from drug to placebo during the extension. The effect lasts only while the drug is taken. The pooled analysis across both trials confirmed the efficacy findings and assembled the strongest safety dataset available [3]. Pooling every available randomized trial, a 2026 analysis confirmed both the visceral and the hepatic fat findings, alongside a favorable metabolic picture with no overall perturbation of glucose [5], although the label still records more people reaching a diabetic HbA1c on the drug than on placebo [8].

Outside the HIV indication, it has improved liver fat in both HIV-positive and HIV-negative groups, reducing intrahepatic lipid and FGF-21 in a small trial of GH augmentation [6]. A 2021 study showed visceral fat quality improving, measured by CT density (a marker of inflammation and metabolic dysfunction in the tissue), independently of how much fat was lost [4]. That suggests the benefit is not only about volume. In people without HIV, a 12-month randomized trial of 60 abdominally obese adults with reduced GH secretion found less visceral fat, lower triglycerides and C-reactive protein, and less carotid thickening than on placebo, with no significant change in weight or glucose [10]. That is one trial in a selected group, and it is not an approved use.

A separate thread looked at GHRH agonists and cognition. A 2012 trial split 152 older adults, some of them mildly cognitively impaired, between tesamorelin at 1 mg a day and placebo across 20 weeks. It found a favorable effect on cognition overall, clearest in executive function, with only a nonsignificant trend in verbal memory [7]. That is one 20-week trial at half the approved dose, which is not enough to establish cognitive efficacy.

Per the FDA label, Egrifta WR is given as 1.28 mg injected under the skin of the abdomen once a day, rotating sites; Egrifta SV is a separate formulation dosed at 1.4 mg once a day, and the two are not interchangeable [8] [9]. The approved use is cutting surplus belly fat in HIV-positive adults who have lipodystrophy. It tells prescribers to monitor IGF-1 and to consider stopping in patients whose IGF-1 stays high, particularly if the response is weak, and it rules out use in pregnancy and in active cancer [8].

Off-label use, including visceral fat in people without HIV, has no published dose-finding study, and this page does not print the schedules off-label prescribers use. Compounded tesamorelin has no lawful route through a licensed US pharmacy.

It was generally well tolerated across the phase 3 trials [1][3]. Injection-site reactions (redness, itching, pain) were the commonest complaint, affecting up to a quarter of participants. Swelling in the limbs and joint pain turned up at low rates. Growth hormone opposes insulin, and the label is explicit about the consequence: by week 26, 5% on tesamorelin against 1% on placebo had an HbA1c of 6.5% or higher, an increased risk of developing diabetes [8]. The pooled 2026 analysis reported no overall perturbation of glucose [5], but an average can hide the minority who cross that line. IGF-1 climbing around 81% is expected rather than alarming, though it warrants monitoring in anyone at risk from IGF-1-sensitive conditions.

It is contraindicated with active malignancy, with a pituitary tumor or previous pituitary surgery, in pregnancy, and in anyone hypersensitive to tesamorelin or any component. Where injected growth hormone at supraphysiological doses is associated with acromegaly, amplifying the body's own pulses leaves the feedback loop intact, which should in theory limit overshoot. What is not known is long-term safety past 52 weeks in HIV populations, or past any duration at all outside them. Compounded material from outside licensed pharmacies adds the usual risks of contamination and mislabeled potency.